Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Promino Nutritional Sciences Inc (MUSL)

CSE
Currency in CAD
Disclaimer
0.24
-0.01(-4.00%)
Delayed Data

MUSL Comments

Stock values for Element Nutritional Sciences have gone up 100% since mid-May lows. This is in credit to the company’s strong reported Q1 results demonstrating significant revenue growth (+559% YoY), wide distribution networks (16k+) and more news including a 2-year exclusive agreement with Dr. James LaVelle representing their patented portfolio of products. Definitely tune into Equity Guru’s Investor Roundtable where $ELMT is in focus. Search the video on YouTube titled: Element Nutritional Sciences (ELMT.C) - Investor Roundtable Video #4
News if you missed it at original publishing - Element Nutritional Sciences has signed Dr. James LaValle to an exclusive two-year agreement to represent their patented product portfolio including Rejuvenate and Promino. Dr. LaValle is a clinical pharmacist and board-certified clinical nutritionist.
Award winning clinical pharmacist and board-certified clinical nutritionist with 35+ years experience practicing wellness, prevention and disease state management, Dr. James LaVelle has signed an exclusive 2-year agreement to represent Elemental Nutrition sciences’ patented Rejuvenate and Promino products. This agreement will see Dr. LaValle appearing on TV and digital campaigns to highlight Element’s unique IP-driven products.
Probably among some of the best results that I've seen from a company this Q. 559% YoY revenue growth with a gross margin of 40%. Plus, sales are only set to grow further as they continue to expand the distribution network and innovate new products (completed production trials for its new Rejuvenate Muscle Activator product for release by Q3). Looking good here.
Element releases their Q1 F'22 results - “We started the year with a milestone quarter highlighted by record revenues of $2.3 million, demonstrating a year-over-year growth of 559%.” With a focused pipeline on further expanded distribution and product launches, the future looks high potential for Element.
ICYMI Aaron from Departures Capital gives a solid breakdown on what to expect from Element Nutritional Sciences. Following the anticipated release of record revenues from Q1 F’22 they are expected to report $2-2.3M in revenues representing a 521% YoY increase. I’m particularly looking forward to how they’ll grow their already impressive distribution at 16k+ retail points throughout this year. ETA for complete results by end of this month. Find the video on YouTube titled: Element Nutritional Sciences to Report Record Revenue in Q1 2022 (CSE:ELMT) (OTC:ELNSF)
Final Q1 results from $ELMT expected before May ends. Preliminary results are painting a solid success story raking in $2-2.3M with an estimated 521% YoY increase at the mid-range from 35-40% gross margins. Market’s certainly reflected that with last week’s green.
Passing the $3M mark a couple weeks ago, Stuart Lowther comments: “Our sales last year were $2.5M for the entire year. So our YoY quarter increase is ~467% over last year. That’s a big growth number we like, but it shows we’re heading in the right direction.” On target $10M run rate. Check out this YouTube video on the Jay Martin Show titled: Massive Growth for Element Nutritional Sciences - ELMT
Preliminary Q1-22 results indicate that Element Nutritional Sciences is expecting to report milestone revenues at $2-2.3M, a 521%+ YoY increase - attributed in part to their impressive distribution channels reaching 16k+ in North America.
Element Nutritional Sciences has a stacked portfolio of patented products that are clinically superior to competitors, massive distribution, and are consistently rated more effective and palpable by customers. This is a solid time to jump in, at discounts of $0.18/share - following this recent $3.5M financing it’s expected to see some upward movement.
Elemental Nutrition Sciences announces closing of $3.5M financing through the issuance of 14M common shares at $0.25/share. The funds raised will be used to accelerate marketing efforts, research and development and general working capital. More details on the offering via Sedar in the company’s short form prospectus from 04/28/22.
Elemental Nutritional Sciences has just announced their Q4 and F’21 results. Overall these results are strong, in particular they’re reporting strong revenue growth at $2.4M in F’21 representing a 156% YoY growth. Accomplishments from the distribution front with currently over 17k retail distribution points and a goal of 20k by 2022, and notes on their innovation pipeline. See the full announcement online
Sharing this new interview with Element Nutritional’s CEO. This is a great overview video with insights on the company’s strong growth trajectories. With a stacked portfolio of patented ready-to-consume products that are clinically proven at fighting age-related muscle loss benchmarking above competitors across all metrics, they are well-positioned to scale distribution and tap into the growing underserved nutrition market addressing nutrition and Sarcopenia what the CDC is calling the new osteoporosis.
The global sarcopenia treatment market size is projected to reach $4.7B by 2030 CAGR 6.1%. Element Nutritional Sciences is seriously well positioned to tap into this growing market, and the CDC has named sarcopenia the next osteoporosis. ELMT’s impressive and patented portfolio boasts some ready-to-drink products that are clinically proven in effectively fighting Sarcopenia and preventing age-related muscle loss. Furthermore, measured against its competitors their Rejuvenate product is scoring superior across all metrics. Already distributed at over 16k+ retail points with a recent Publix distro update, they also have potential to expand into institutional and healthcare markets as well.
Despite the volatile market conditions, $ELMT has found stability in the $0.30 range. But, considering the 16,500+ stores, patented formulas, and $30M market cap, this seems pretty undervalued at these levels. I'm interested in seeing the financial results as a past news release said they should be expected to be reported this month. GLTA!
Element Nutritional Sciences has been seeing some nice green in the past week. Feeling highly optimistic with them having a sophisticated distribution structure having products sold at 16K+ retail points including 1,300 Publix locations. Their patented portfolio is the real deal with clinical studies proving their efficacy in fighting Sarcopenia and preventing age related muscle loss - they’ve also been measured against their competitors and have scored superior across all metrics.
Rejuvenate and Promino are the key patented formulas in Element’s portfolio. Their products have been benchmarked against peers in the massive $314B nutritional space, and the data shows that Rejuvenate is superior to its competitors across all metrics in preventing age related muscle loss (and Sarcopenia).Promino is the other patent and an evolution of protein supplements with a higher DIAAS rating than other sources of protein (including whey) that simply can’t compare to this absorption rate. Clinical studies for Promino report a 40.8% increase in strength compared to placebo groups. Element Nutritional products are already available at 20,000+ retail and ecommerce locations with the US’ 3rd largest grocery chain, Publix recently announcing distribution.Lots of info out there re:Rejuvenate, but worth looking into the info about Promino as well - there is strong potential this portfolio can extend into institutional markets too.
With patented ready-to-drink muscle health and repair supplements and the innovative sports nutrition product, the Element Nutritional Sciences portfolio is stacked with realized sci-fi technology with a proprietary formula proven superior to its competitors across all metrics in preventing age related muscle loss. Available in over 16k retail points, they’re strongly positioned to tap into and disrupt the $314B human nutrition market with products strongly suited for the significantly underserved and growing 45+ demographic.
This Canadian based nutraceutical company has a patented flagship ready-to-drink product, Rejuvenate that is scientifically proven to prevent age related muscle loss. There’s a lot to get behind and excited about regarding this micro-cap play, they have distribution at over 16k+ retail points and just recently announced an expansion with Publix, the US’ 3rd largest grocer.
Element Nutritional Sciences is disrupting the massive nutrition space with a patented formula targeting the underserved 45+ demographic with Rejuvenate, a ready-to-drink product eliminating muscle loss in the elderly. Already available in 16K+ retailers and recently penned distribution with Publix.
Solid move for Element Nutritional Sciences announcing expanded distribution with the 3rd Largest US grocery chain, Publix - Their flagship product “Rejuvenate” is now available at 15.6K+ distribution points.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.